https://doi.org/10.55788/74e71270
The draft revision of the McDonald diagnostic criteria for MS is an initiative of the International Advisory Committee on Clinical Trials in MS, presided by Prof. Xavier Montalban (Vall d'Hebron University Hospital, Spain). He presented the most important upcoming revisions to the 2017 version of the McDonald criteria [1,2]. Prof. Montalban stressed the importance of these criteria as they impact the patient-clinician dialogue, treatment decisions (although diagnostic criteria do not equal treatment guidelines), clinical trials, and the prognosis of MS.
The first and most fundamental change Prof. Montalban mentioned, was that RIS can be considered MS in specific situations. This allows for the diagnosis of MS in asymptomatic individuals. “This means we are moving towards a biological diagnosis, which is happening as well in other neurodegenerative conditions such as Alzheimer's and Parkinson's disease.” A patient with RIS may be diagnosed with MS if he fulfils the criteria for both DIT and dissemination in space (DIS) —damage in at least 2 of 5 anatomical locations in the nervous system.
The other proposed revisions include:
- DIT is no longer required.
- The optic nerve may serve as a fifth anatomical location to demonstrate DIS —assessed by MRI, visual evoked potential, or optical coherence tomography— if no better explanation for optic nerve pathology can be found.
- Updated DIS criteria: DIS criteria are fulfilled when 2 out of 5 topographies show typical lesions, whether these are symptomatic or not.
- Criteria for the diagnosis of primary progressive MS and relapsing MS are now the same.
- Paraclinical evidence is needed to diagnose MS.
- Kappa-free light chain is a diagnostic marker for MS.
- Central vein sign and a paramagnetic rim lesion are added as optional tools to help diagnose MS in certain situations.
- Stricter features should be used to diagnose MS in individuals >50 years of age with headache disorders (including migraine) or with vascular disorders.
- Laboratory tests are recommended to confirm the diagnosis in children and adolescents.
- Montalban X. Revised McDonald criteria 2023. Scientific Session 1, ECTRIMS 2024, 18–20 September, Copenhagen, Denmark.
- Thompson AJ, et al. Lancet Neurol. 2018;17(2):162-73.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Approaches to RIS and MS converge Next Article
Registry participation can enhance quality of rheumatology care »
« Approaches to RIS and MS converge Next Article
Registry participation can enhance quality of rheumatology care »
Table of Contents: ECTRIMS 2024
Featured articles
Diagnosis, Biomarkers, and Phenotypes
Revised McDonald criteria allow earlier and more precise MS diagnosis
Approaches to RIS and MS converge
AI versus clinicians: who diagnoses MS faster and better?
Blood markers predict MS progression
Gut microbiota modulate inflammation and cortical damage
Risk factors and importance of persistent PIRA
Vitamin D supplementation in progressive MS should be medically supervised
Treatment: Strategies
Encouraging real-world results of AHSCT to treat aggressive MS
CAR T-cell therapy in MS: in its infancy but highly anticipated
B cell-tailored dosing of ocrelizumab shows good results
First-line moderate-efficacy DMTs show similar efficacy
Treatment: Trials
Tolebrutinib slows disability worsening in relapsing MS
Frexalimab shows favourable safety and efficacy in OLE
Good safety of ozanimod over up to 8 years of treatment
Tolebrutinib slows disability in non-relapsing SPMS
High-dose simvastatin does not slow disability progression in SPMS
Comorbidity Risks and Pregnancy
High genetic burden for depression associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
Transfer of ocrelizumab into breastmilk is negligible
NMOSD/MOGAD
Ineffective response to EBV in MS not seen in similar diseases
Comparative effectiveness and safety of DMTs in NMOSD
Age, time, and treatment determine relapse risk in MOGAD
Related Articles
April 14, 2022
Telerobotics may enable remote-controlled stroke surgery
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com